Particularly in ovarian cancer, several miRNAs (e.g., miR-142-5p, miR-181c, and miR-1271) modulate the sensitivity of tumoural cells to cisplatin and/or paclitaxel-based therapies, mainly through modulation of the PI3K/Akt/mTOR axis [56,57,58]. This evidence concerns the gene MTOR and ovarian cancer.